GT-0002X is under clinical development by Gene Therapy Research Institution and currently in Phase II for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency. According to GlobalData, Phase II drugs for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GT-0002X LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of Parkinson's disease and Aromatic l-Amino Acid Decarboxylase (AADC) deficiency. It is administered through intraputaminal and intracerebral route as a infusion. It constitutes Adeno-associated virus (AAV) which encodes for the enzyme human aromatic L-amino acid decarboxylase.
For a complete picture of GT-0002X’s drug-specific PTSR and LoA scores, buy the report here.